A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

  • End date
    Dec 30, 2022
  • participants needed
  • sponsor
    Sihuan Pharmaceutical Holdings Group Ltd.
Updated on 25 January 2021


This study includes Single agent/combination dose exploration study and the phase II study. The primary purpose of this study is to determine the maximum tolerated dose(MTD)/recommended phase II dose(RP2D) of XZP-3287 and its efficacy and safety in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.

Condition Advanced Breast Cancer, Metastasis Solid Tumors
Treatment XZP-3287
Clinical Study IdentifierNCT04539496
SponsorSihuan Pharmaceutical Holdings Group Ltd.
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Single agent and combination dose exploration studyPatient is an adult male/female 18~70 years old; the phase II studyPatient is an adult male/female 18 years old
Single agent dose escalation study Patients with a histologically or cytologically confirmed diagnosis of a solid tumor for which Standard treatment failure or no further effective standard treatment is available
Combination dose exploration studyPatients with locally advanced or metastatic
breast cancer with hormone receptor positive (HR+) and her2-negative (HER2-)
were not eligible for surgical resection or radiotherapy for the purpose of
cure, and had no clinical indications for chemotherapy, and received endocrine
therapy 1 line
The phase II study: Locally advanced or metastatic breast cancer diagnosed
histologically or cytologically not suitable for surgery or radical
radiotherapy; HR+ and HER2- ; have locally advanced disease not amenable to
curative treatment by surgery or metastatic disease; progress after previous
endocrine therapy; at least 1 chemotherapy regimen in the previous adjuvant or
metastasis contains paclitaxel or capecitabine; there should be no more than 2
chemotherapy regimens in the recurrent or metastatic stage
At least one measurable lesion (based on RECIST v1.1)
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Have recovered from the acute effects of therapy (until the toxicity resolves to either baseline or Grade 1) except for residual alopecia
Adequate organ and marrow function
The life expectancy of the patient was determined by the investigator to be 12 weeks
Fertile male or female patients must agree to use an effective contraceptive method during the study period and for three months after the last study medication
Patient has signed informed consent before any trial related activities

Exclusion Criteria

Single agent and combination dose exploration studyPatients with known uncontrolled or symptomatic CNS metastases; The phase II studyHave central nervous system (CNS) metastasis, or Have visceral crisis, or Inflammatory breast cancer
Have received an autologous or allogeneic stem-cell transplant
Patient has impairment of gastrointestinal (GI) function or GI disease
Single agent and combination dose exploration studyAny other malignancy was diagnosed within 3 years prior to enrollment, except for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix, which is adequately treated and the disease is stable
The phase II studyHave a history of any other cancer (except nonmelanoma skin
cancer or carcinoma in-situ of the cervix), unless in complete remission with
no therapy for a minimum of 3 years
Subject has impaired cardiac function or heart disease of clinical significance
Cerebrovascular accidents within 6 months before enrollment, including a history of transient ischemic attack or stroke
Major surgery or surgical treatment due to any cause occurred within 4 weeks prior to enrollment
Presence of any serious and/or uncontrolled disease in the opinion of the investigator that may interfere with the study assessment
Uncontrollable pleural effusion, peritoneal effusion, pericardial effusion in the 4 weeks before the first administration (except for a small amount of effusion detected by imaging examination)
A prior history of definite neurological or psychiatric disorders, including epilepsy or dementia
Chronic active HBV, HCV or HIV diseases
Patient who received any CDK4/6 inhibitor or patients who plan surgery, or the investigator determines that surgery or radical radiation therapy is required
Participation in a prior treatment of chemotherapy, radiotherapy, endocrinotherapy, targeted therapy, immunotherapy and any investigational study within 14 days prior to enrollment
Bone marrow suppression therapy, such as GCS-F, EPO, or blood transfusion, was administered within 14 days prior to enrollment
Patient with a known hypersensitivity to any of the excipients in this study
Pregnant or breastfeeding
The researchers considered that there were some cases that were not suitable for inclusion
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note